Core PKU Symptoms Sapropterin Targets
Sapropterin (Kuvan) reduces elevated blood phenylalanine (Phe) levels in phenylketonuria (PKU) patients responsive to the drug. High Phe is the hallmark biochemical symptom of PKU, stemming from deficient phenylalanine hydroxylase (PAH) enzyme activity, which sapropterin—a synthetic tetrahydrobiopterin (BH4) cofactor—helps restore.[1][2]
How Sapropterin Works on Symptoms
It enables partial PAH function, lowering Phe enough to prevent or lessen neurological damage. Responsive patients (about 20-50% of those with PAH mutations) see Phe drops of 30% or more within weeks, addressing the root cause rather than downstream effects.[1][3]
Which Neurological Symptoms Improve
Sapropterin primarily alleviates Phe-driven symptoms like:
- Cognitive delays and intellectual disability (improved IQ and development scores in trials).
- Behavioral issues such as ADHD-like attention deficits and hyperactivity.
- Seizures and mood disturbances linked to chronic high Phe.[2][4]
It does not reverse existing severe brain damage from undiagnosed PKU but slows progression in treated cases.
Symptoms It Does Not Alleviate
Sapropterin has no direct effect on non-neurological PKU signs like eczema, musty body odor, or lighter skin/hair pigmentation, which tie to Phe buildup but persist despite Phe reduction.[1][2]
Who Responds and Testing Process
Response depends on specific PAH mutations; a 30-day Phe reduction trial (with diet) confirms eligibility. Children under 4 show best neurodevelopmental gains.[3][5]
Clinical Trial Evidence
Pivotal studies (e.g., Phase 3 trials) showed 10 mg/kg/day sapropterin cut mean Phe by 36% in responsive kids aged 4-12, with parallel gains in executive function and attention tests versus placebo.[4][6]
[1]: FDA Label for Kuvan (sapropterin)
[2]: NORD: Phenylketonuria Overview
[3]: BioMarin Patient Site: Kuvan Mechanism
[4]: NEJM: Sapropterin Trial in PKU (2007)
[5]: ACMG Guidelines: PKU Management
[6]: Pediatrics: Long-term Sapropterin Outcomes (2013)